Gyre Therapeutics (GYRE) Net Margin (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Net Margin of 38.59% for Q1 2026, down 5083.0% year-over-year from 0.77% in Q1 2025, and down 733.14% quarter-over-quarter from 4.63% in Q4 2025.
Gyre Therapeutics (GYRE) Net Margin (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Net Margin for 16 consecutive years, with 38.59% the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Margin fell 5083.0% year-over-year to 38.59%; the TTM figure through Mar 2026 stood at 5.44% (down 1264.0% YoY), while the FY2025 annual figure was 4.31%, down 712.0% from the prior year.
- Net Margin slipped to 38.59% in Q1 2026 per GYRE's latest filing, from 4.63% in the prior quarter.
- Across five years, Net Margin topped out at 27.72% in Q1 2024 and bottomed at 1830.73% in Q1 2022.
- Historically, Net Margin has averaged 145.09% across 5 years, with a median of 4.41% in 2024.
- On a YoY basis, Net Margin climbed as much as 183973 bps in 2023 and fell as far as 34259 bps in 2023.
- Gyre Therapeutics' Net Margin stood at 29.47% in 2022, then plunged by 1163 bps to 372.06% in 2023, then soared by 100 bps to 0.36% in 2024, then tumbled by 1204 bps to 4.63% in 2025, then slumped by 733 bps to 38.59% in 2026.
- Business Quant data shows GYRE's Net Margin at 38.59% in Q1 2026, 4.63% in Q4 2025, and 11.81% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | -40.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -40.07% |
| Mar 31, 2026 | -38.59% |
| Dec 31, 2025 | -4.63% |
| Sep 30, 2025 | 11.81% |
| Jun 30, 2025 | 1.65% |
| Mar 31, 2025 | 12.23% |
| Dec 31, 2024 | -0.36% |
| Sep 30, 2024 | 4.41% |
| Jun 30, 2024 | 13.99% |
| Mar 31, 2024 | 27.72% |
| Dec 31, 2023 | -372.06% |
| Sep 30, 2023 | 12.41% |
| Jun 30, 2023 | 6.32% |
| Mar 31, 2023 | 9.00% |
| Dec 31, 2022 | -29.47% |
| Mar 31, 2022 | -1,830.73% |
| Dec 31, 2021 | -873.98% |
| Sep 30, 2021 | -1,097.78% |
| Jun 30, 2021 | -1,760.42% |
| Mar 31, 2021 | -1,529.52% |